文献速递腹部US

Sonazoid超声造影肝血管瘤低增强特征及影响因素:多中心研究

Sonazoid Contrast-Enhanced Ultrasound Hypoenhancement Characteristics and Influencing Factors of Hepatic Hemangiomas: A Multicenter Study.
PubMed 文献 · Ultrasound Med Biol · 2026-04-02

这项前瞻性多中心研究纳入26个中心136例肝血管瘤患者,分析Sonazoid超声造影移行期和Kupffer期低增强现象的模式及影响因素。Kupffer期低增强发生率为55.9%,以轻度低增强为主,低增强多在4分钟后出现且随时间逐渐增加。二维超声低回声和最大径>2cm是Kupffer期低增强的独立影响因素。

要点

  • Sonazoid Kupffer期肝血管瘤低增强发生率高达55.9%,轻度低增强为主要模式。
  • 低增强多在4分钟后开始出现,中位时间5.5分钟,随时间延长发生率逐渐增加。
  • 二维超声低回声及最大径>2cm的血管瘤更易出现Kupffer期低增强。

关键影像表现/征象

  • Kupffer期低增强发生率为55.9%(76/136),其中轻度低增强占41.9%(57/136),明显低增强占14.0%(19/136)。
  • 高增强占5.9%(8/136),等-高增强占38.2%(52/136)。
  • 低增强发生率与时间点呈显著正相关(rs=0.993,p<0.001)。
  • 低增强主要开始时间为4分钟(p<0.001),低增强组中位低增强时间为5.5分钟。

诊断标准与关键数值

  • Kupffer期低增强的独立影响因素:二维超声低回声病灶较回声增高病灶更易低增强(HR=1.80,95%CI:1.10-2.95,p=0.020)。
  • 病灶≥5cm较<2cm更易低增强(HR=2.58,95%CI:1.18-5.65,p=0.018);病灶2-5cm较<2cm更易低增强(HR=2.32,95%CI:1.35-3.97,p=0.002)。

临床应用与阅片要点

  • Sonazoid超声造影评估肝血管瘤时,Kupffer期低增强并非少见,不应仅凭低增强误判为恶性。
  • 低增强多在4分钟后出现,观察Kupffer期应至少延迟至4-5分钟以上,避免过早判断。
  • 二维超声低回声且最大径>2cm的血管瘤,Kupffer期低增强可能性更高,报告时应结合二维特征综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Given the high hypoenhancement prevalence of hepatic hemangiomas (HHs) during the transitional phase and Kupffer phase (KP) of Sonazoid contrast-enhanced ultrasound (CEUS), this study aimed to investigate the hypoenhancement phenomenon pattern and its influencing factors.

METHODS: This was a prospective multicenter study. A total of 136 patients with HHs were enrolled from 26 medical centers, including 76 cases in the KP hypoenhancement group and 60 cases in the KP non-hypoenhancement group. Enhancement characteristics and patterns at different time points during the transitional phase were analyzed between the two groups. Statistical analyses included Mann-Whitney U test for two independent samples, chi-square test or Fisher's exact test for categorical variables and Spearman's rank correlation analysis for the relationship between hypoenhancement prevalence and time points. Survival analysis was used to compare differences in the start time of hypoenhancement among HHs with different characteristics. Multivariate Cox regression analysis was performed to identify the influencing factors of KP hypoenhancement.

RESULTS: The hypoenhancement prevalence of HHs in the KP was 55.9% (76/136). The proportions of hyperenhancement, isohyperenhancement, mild hypoenhancement and marked hypoenhancement were 5.9% (8/136), 38.2% (52/136), 41.9% (57/136) and 14.0% (19/136), respectively. There was a significant positive correlation between the hypoenhancement prevalence and time points (rs = 0.993, p < 0.001). The main start time of hypoenhancement was 4 min (p < 0.001). The median hypoenhancement time in the KP hypoenhancement group was 5.5 min. Two-dimensional ultrasound (2-D-US) echo type and maximum diameter were independent influencing factors for Sonazoid KP hypoenhancement: hypoechoic lesions were more likely to present hypoenhancement compared with hyperechoic ones (HR = 1.80, 95% CI: 1.10-2.95, p = 0.020); both lesions ≥5 cm and those between 2 and 5 cm had a higher likelihood of hypoenhancement compared with lesions <2 cm, with HR = 2.58 (95% CI: 1.18-5.65, p = 0.018) and HR = 2.32 (95% CI: 1.35-3.97, p = 0.002), respectively.

CONCLUSION: More than half of HHs show hypoenhancement in the KP of Sonazoid CEUS, and mild hypoenhancement is the main enhancement pattern among hypoenhancement cases. Hypoenhancement mostly occurs after 4 min, and the hypoenhancement prevalence gradually increases over time. The independent influencing factor for KP hypoenhancement is 2-D-US hypoechogenicity and maximum diameter greater than 2 cm.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Luo Y, Wen D, Liu J, et al. Sonazoid Contrast-Enhanced Ultrasound Hypoenhancement Characteristics and Influencing Factors of Hepatic Hemangiomas: A Multicenter Study. Ultrasound Med Biol. 2026. PMID: 41934080. doi:10.1016/j.ultrasmedbio.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。